Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Clene Inc (CLNN)

Clene Inc (CLNN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Clene (NASDAQ: CLNN) Issues Update on NIH-Funded Program for CNM-Au8® in ALS

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health...

CLNN : 0.3270 (-0.61%)
Clene (NASDAQ: CLNN) Participates in Three Investor Conferences During May 2024

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic...

CLNN : 0.3270 (-0.61%)
Clene (NASDAQ: CLNN) Looking to Transform Healthcare for Individuals with Neurodegenerative Diseases

Clene (NASDAQ: CLNN) has innovated CNM-Au8(R), an oral nanotherapeutic designed to revitalize the brain’s mitochondrial function, which is a significant advancement for the treatment of neurodegenerative...

CLNN : 0.3270 (-0.61%)
Clene (NASDAQ: CLNN) Announces Operational Highlights as part of Q1 2024 Financial Results

Clene (NASDAQ: CLNN), a late-stage clinical biopharmaceutical company dedicated to revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple...

CLNN : 0.3270 (-0.61%)
Clene (NASDAQ: CLNN) Announces Participation Schedule for May Conferences

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial...

CLNN : 0.3270 (-0.61%)
Clene (NASDAQ: CLNN) Releases Q1 2024 Financial Numbers, Operation Highlights

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., are reporting on first-quarter 2024 financial results and operating highlights for its CNM-Au8 clinical program for amyotrophic...

CLNN : 0.3270 (-0.61%)
Clene (NASDAQ: CLNN) Presents Findings on Phase 2 VISIONARY-MS LTE at American Academy of Neurology Annual Meeting

Clene (NASDAQ: CLNN), along with its subsidies, “Clene”, and its wholly owned subsidiary Clene Nanomedicine, Inc., a pioneering clinical-stage biopharmaceutical firm dedicated to enhancing mitochondrial...

CLNN : 0.3270 (-0.61%)
Clene (NASDAQ: CLNN) Continues Development of CNM Au8(R) for Neurodegenerative Diseases

In recognition of April as Parkinson’s Disease Awareness Month, IBN is highlighting Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and...

CLNN : 0.3270 (-0.61%)
Clene (NASDAQ: CLNN) Announces Study Results for CNM-Au8 as MS Treatment Presented at AAN Conference

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., announced that results from a phase 2 Visionary-MS long-term extension (“LTE”)...

CLNN : 0.3270 (-0.61%)
Clene (NASDAQ: CLNN) Looking to Advance Discussions for Accelerated Approval, New NDA for CNM-Au8(R)

Clene (NASDAQ: CLNN), alongside its wholly owned subsidiary Clene Nanomedicine Inc., is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function...

CLNN : 0.3270 (-0.61%)

Barchart Exclusives

Grain Market Update: What's Affecting the Corn, Wheat, and Soybean Markets?
On Friday I was interviewed by Michelle Rook on AgWeb's Markets Now. I spoke about the recent action in the corn, wheat, and soybean markets. In addition, we discussed the cattle markets. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar